Main Content

Press Releases

Home / Investors / Press Releases

Dr. Heiner Dreismann, Former CEO of Roche Molecular Systems and Diagnostics Veteran, Joins MyDx Executive Advisory Board

Dr. Dreismann To Also Serve as Chairman of the Executive Advisory Board; Assist MyDx In Seeking Development Partners and Strategic Partners 

San Diego, CA, April 24, 2018 (GLOBE NEWSWIRE) -- MyDx, Inc. (OTC: MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to understand the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced that Heiner Dreismann, Ph.D., has joined as the company’s Chairman of the Executive Advisory Board.  Under Dr. Dreismann’s leadership as Chief Executive Officer of Roche Molecular Systems, Roche became the global leader in molecular diagnostics by a significant expansion of their portfolio of molecular tests and respective instrumentation. Prior to his appointment as Chief Executive Officer of Roche Molecular Systems, Dr. Dreismann held several other senior positions within Roche, including head of Global Business Development for Roche Diagnostics, Business Unit Europe Manager for PCR, head of Business Unit for Microbiology, as well as R&D positions in microbiology and infectious diseases and the head of manufacturing for infectious disease diagnostics.

MyDx CEO Daniel Yazbeck commented, “Dr. Dreismann is a top industry expert in the field of molecular and medical diagnostics.  He has a proven track-record of leadership in the development, commercialization and adoption of diagnostics, and brings valuable real-world experience as we continue to develop our advance our smart devices and data monetization strategies in 2018.”  

“Our focus will continue to be getting more of the MyDx diagnostic tools into consumers’ hands,” continued Yazbeck. “Dr. Dreismann, throughout his impressive career and consistent successful track record, has developed numerous domestic and international industry contacts which we believe will open doors for our company.  We are very pleased to welcome Dr. Dreismann to MyDx and look forward to his active participation and contribution to our success.”

Dr. Dreismann added, “After having spent time with Mr. Yazbeck and learning more about his vision for MyDx as a leader in science based cannabis health technology, I am pleased to be a part of the team that has developed the first consumer diagnostic that will bring true innovation to personalized medicine.  It is my intent to be an active member of the Advisory Board and as I develop a deeper understanding to become even more active with the Company. I intend to bring my experience and contacts, which I believe can create real opportunities for our business as we develop products and seek licensing partners for our technologies.”

Dr. Dreismann holds a Masters Degree in Biology and a Ph.D. in Microbiology/Molecular Biology (summa cum laude) from Westfaelische Wilhelms University in Muenster, Germany.

To learn more about MyDx, please visit www.mydxlife.com.

About MyDx, Inc.

MyDx, Inc. (OTC:MYDX) is a chemical detection and sensor technology company based in San Diego, California whose mission is to help people Trust & Verify® what they put into their minds and bodies. The Company’s first product, MyDx®, also known as “My Diagnostic”, is a patented multiuse hand-held chemical analyzer designed to help consumers and professional test for pesticides in food, chemicals in water, toxins in the air, and the safety and potency of cannabis samples, which is the initial focus of through the CannaDxTM application.  CannaDx users have submitted over 40,000 crowdsourced data points revealing the chemical profile of the cannabis they are consuming and how its making them feel which feeds a data analytics platform, a SaaS business, as well as the biopharmaceutical division of MyDx.  The company is committed to addressing areas of critical national need to promote public safety, transparency and regulation in the various markets we serve and hence its more immediate mission is to continue to develop smart devices as part of an ecosystem that crowdsources consumer generated preclinical data to drive innovation in the cannabis industry.  For more information, please visitwww.mydxlife.com.

Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at http://ir.cdxlife.com/all-sec-filings or www.sec.gov.

Investor Contact:

MyDx Shareholder Communications

800.814.4550 ext. 4

ir@mydxlife.com

Primary Logo

Source: MyDx, Inc.